(RTTNews) - Zealand Pharma A/S (ZEAL.CO) said Thursday that Boehringer Ingelheim's investigational Survodutide met its co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial in adults with obesity or overweight and type 2 diabetes.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.